SUPERNUS PHARMACEUTICALS, INC.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
The Company expects Roman Bradel, Ph.D. to join the Company in March 2024 as its Vice President, Regulatory Affairs reporting to Frank Mottola, the Company’s Senior Vice President, Quality, GMP Operations and IT.
Tami T. Martin, R.N., Esq., the Company’s Senior Vice President, Regulatory Affairs, notified Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) of her retirement from the Company effective May 3, 2024.
Extracted from this filing and checked against the source text.
Roman Bradel was appointed as Vice President, Regulatory Affairs at SUPERNUS PHARMACEUTICALS, INC..
The Company expects Roman Bradel, Ph.D. to join the Company in March 2024 as its Vice President, Regulatory Affairs reporting to Frank Mottola, the Company’s Senior Vice President, Quality, GMP Operations and IT.View on SEC.gov
Tami T. Martin retired as Senior Vice President, Regulatory Affairs at SUPERNUS PHARMACEUTICALS, INC..
Tami T. Martin, R.N., Esq., the Company’s Senior Vice President, Regulatory Affairs, notified Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) of her retirement from the Company effective May 3, 2024.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.